Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Inclusion Criteria: * Patients confirmed relapsed or refractory PCL who previously untreated or never received treatment with Bortezomib * KPS ≥ 60 * Adequate liver and renal function within 2 weeks of Screening: * Bilirubin ≤ 1.5 × the upper limit of normal (ULN) * Alanine aminotransferase (ALT) ≤ 2.5 × the upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤ 2.5 × the upper limit of normal (ULN) * Cardiac function \> Ⅲ grade and ejection fraction \> 45% * Signed informed consent prior to initiation of any study-related procedures that are not considered standard of care Exclusion Criteria: * has taken Bortezomib * KPS ≤ 60 scores * mental illness